section name header

Indications ⬇

High Alert

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: orthostatic hypotension.

Derm: flushing, sweating.

EENT: blurred vision, diplopia, miosis.

Endo: adrenal insufficiency.

GI: constipation, GI obstruction, choking, dry mouth, nausea, vomiting.

GU: urinary retention.

Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams.

Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA).

Misc: physical dependence, psychological dependence, tolerance.

Interactions ⬆ ⬇

Drug-Drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Larger doses may be required during chronic therapy. ER capsules are NOT bioequivalent to ER tablets.

Hepatic Impairment

  • PO (Adults): ↓ initial dose by 50–66%.

US Brand Names ⬆ ⬇

Oxaydo, OxyCONTIN, Roxicodone, Roxybond, Xtampza ER

Action ⬆ ⬇

Therapeutic Effects:

Classifications ⬆ ⬇

Therapeutic Classification: opioid analgesics

Pharmacologic Classification: opioid agonists, opioid agonists nonopioid analgesic combinations

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed from the GI tract.

Distribution: Widely distributed. Crosses the placenta; enters breast milk.

Protein Binding: 38–45%.

Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A4 isoenzyme, and to a lesser extent by the CYP2D6 isoenzyme.

Half-life: 2–3 hr.

Contr. Subst. Schedule ⬆ ⬇

Schedule II (C-II)

Canadian Brand Names ⬆ ⬇

Oxy IR, OxyNEO, Supeudol

Time/Action Profile ⬆ ⬇

(analgesic effects)

ROUTEONSETPEAKDURATION
PO10–15 min60–90 min3–6 hr
PO-ER†10–15 min3 hr12 hr

†Extended-release.

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

ox-i-KOE-done audio

Code ⬆

NDC Code*